cd19-car-dnt cells
Cell therapyexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2022 (NCT05453669)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06314828 | Phase 1 | May 20, 2024 | Government of China, Jiao Tong University, Southern Medical University |
| NCT06340490 | Phase 1 | May 15, 2024 | Changhai Hospital, Government of China, Jiao Tong University, Nanjing University, Peking University |
| NCT06316076 | Phase 1 | Oct 30, 2023 | Government of China, Jiao Tong University |
| NCT05453669 | Phase 1 | Jun 15, 2022 | Government of China, Zhejiang University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 2 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 3 | 1 | 1 | 2023 |
| Changhai Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
7 organizations
Page 1 / 1